Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Assets (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Current Assets for 15 consecutive years, with $2.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 46.27% year-over-year to $2.5 billion, compared with a TTM value of $2.5 billion through Dec 2025, up 46.27%, and an annual FY2025 reading of $2.5 billion, up 46.27% over the prior year.
  • Current Assets was $2.5 billion for Q4 2025 at Neurocrine Biosciences, up from $2.2 billion in the prior quarter.
  • Across five years, Current Assets topped out at $2.5 billion in Q4 2025 and bottomed at $1.0 billion in Q3 2021.
  • Average Current Assets over 4 years is $1.6 billion, with a median of $1.6 billion recorded in 2023.
  • The sharpest move saw Current Assets decreased 13.07% in 2021, then soared 46.27% in 2025.
  • Year by year, Current Assets stood at $1.0 billion in 2021, then surged by 59.79% to $1.6 billion in 2023, then grew by 7.32% to $1.7 billion in 2024, then skyrocketed by 46.27% to $2.5 billion in 2025.
  • Business Quant data shows Current Assets for NBIX at $2.5 billion in Q4 2025, $2.2 billion in Q3 2025, and $1.7 billion in Q2 2025.